Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Celerion | INDUSTRY |
| Syneos Health | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary goal of this study is to evaluate an alternative myeloablative, but reduced toxicity conditioning regimen in children, to describe the safety and efficacy of intravenous (i.v.) Treosulfan administered as part of a standardised Fludarabine-containing conditioning and to contribute to the current pharmacokinetic model to be able to finally give age (or body surface area) dependent dose recommendations. The treatment regimens given in the protocol MC-FludT.17/M are based on sufficient clinical safety and efficacy data. Considering the vital indication for allogeneic haematopoietic stem cell transplantation of the selected patient population, the risk-benefit assessment is therefore reasonably in favour of the study conduct.
The protocol MC-FludT.17/M is a clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in at least 70 paediatric patients with haematological malignancies (male and female children with haematological malignant diseases as acute lymphoblastic leukaemias (ALL), acute myeloid leukaemias (AML), myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukaemias (JMML), requiring myeloablative conditioning treatment with following allo-HSCT).
Treosulfan dose per day is to be calculated by using body surface area (BSA). Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen and the other consists of an intensified regimen with Fludarabine and ThioTEPA.
Freedom from transplant (treatment)-related mortality (TRM), defined as death from any transplant-related cause from the day of first administration of study medication until day +100 after HSCT is the primary objective of the trial.
Moreover, the current pharmacokinetic (PK) model should be contributed to be able to finally give age (or BSA) dependent dose recommendations.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treosulfan | Experimental | Treosulfan dose per day is to be calculated by using BSA. One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours. Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B. Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Treosulfan | Drug | Treosulfan dose per day is to be calculated by using BSA: One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours. Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B. Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2. |
| Measure | Description | Time Frame |
|---|---|---|
| Freedom from transplant (treatment)-related mortality (TRM) | TRM is defined as death from any transplant-related cause | from the day of first administration of study medication until day +100 after HSCT |
| Measure | Description | Time Frame |
|---|---|---|
| Engraftment after HSCT | Engraftment is defined as first of three consecutive days for each of the following four criteria:
| until engraftment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ajay Vora, MD, Prof. | Great Ormond Street Hospital NHS Trust | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Anna Children Hospital | Vienna | A-1090 | Austria | |||
| University Hospital Motol, Charles University, Prague |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32203268 | Derived | Kalwak K, Mielcarek M, Patrick K, Styczynski J, Bader P, Corbacioglu S, Burkhardt B, Sykora KW, Drabko K, Gozdzik J, Fagioli F, Greil J, Gruhn B, Beier R, Locatelli F, Muller I, Schlegel PG, Sedlacek P, Stachel KD, Hemmelmann C, Moller AK, Baumgart J, Vora A. Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Transplant. 2020 Oct;55(10):1996-2007. doi: 10.1038/s41409-020-0869-6. Epub 2020 Mar 20. |
| Label | URL |
|---|---|
| sponsor's homepage | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Safety including early toxicity until day +100 after HSCT, serious adverse reactions (SARs) until the end of the longer-term follow-up phase | based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 | until 12 months after HSCT |
| Hepatic sinusoidal obstruction syndrome (HSOS), lung toxicity (CTCAE term pulmonary fibrosis), hepatic toxicity and infections of any CTCAE grade (non-serious and serious) | until day +100 after HSCT |
| Donor-type chimerism | The incidences of complete donor-type chimerism will be estimated as the number of patients with complete chimerism divided by the total number of patients at risk. | on day +28, day +100 and 12 months after HSCT |
| Non relapse mortality (NRM), transplant related mortality (TRM), graft failure rate, incidence of relapse/progression, relapse-free/progression-free survival (RFS/PFS) and overall survival (OS) | Non-relapse mortality will be defined as the probability of dying in the absence of persisting disease or previous occurrence of relapse/progression or graft failures. TRM is defined as the probability of dying from a transplant-related cause. The associated time span is defined as the interval from day 0 to death due to a transplant-related cause. The incidence of relapse/progression is defined as the probability of having relapse/progression of the underlying disease. Relapse-free/progression-free survival is defined as the time length between day 0 and the date of relapse/progression of the underlying disease or death due to any cause. OS after HSCT is defined as the probability of surviving. Survival time is defined as the time period between day 0 and the day of death due to any cause. Kaplan-Meier methods will be applied for estimating the probability of these parameters over time. | after 12 months after HSCT and until the end of the longer-term follow-up phase |
| Incidence and severity of acute (until day +100) and chronic (until 12 months after HSCT) graft versus host disease (aGvHD/cGvHD) | The probability of grade I-IV and grade III-IV aGvHD will be estimated by cumulative incidence rates and summarised for selected time points together with their approximate 90 % confidence intervals. As for aGvHD, the probability of cGvHD will be estimated by cumulative incidence rates. | until 12 months after HSCT |
| Use of rescue therapies including donor-lymphocyte infusions (DLIs) and further conditioning regimens | until 12 months after HSCT |
| PK parameters of Treosulfan and its epoxides | The following PK parameters of Treosulfan and its epoxides will be measured: Clearance (CL); volume of distribution (Vss); terminal elimination rate constant (λz); terminal elimination half-life (t1/2); area under the concentration time curve from time zero to infinity (AUC∞); maximum observed concentration (Cmax, i.e. C end of infusion). | day -6 prior to HSCT |
| Prague |
| 150-06 |
| Czechia |
| University Clinic Düsseldorf | Düsseldorf | 40225 | Germany |
| University Clinic Erlangen-Nürnberg | Erlangen | 91054 | Germany |
| Universitätsklinikum Essen | Essen | 45147 | Germany |
| University Hospital Johann Wolfgang Goethe | Frankfurt | 60590 | Germany |
| University Clinic Hamburg-Eppendorf | Hamburg | 20246 | Germany |
| Medical University Hannover | Hanover | 30625 | Germany |
| University Clinic Heidelberg | Heidelberg | 69120 | Germany |
| University Clinic Jena | Jena | 07740 | Germany |
| University Clinic München | München | 80804 | Germany |
| University Clinic Münster | Münster | 48129 | Germany |
| University Clinic Regensburg | Regensburg | 93053 | Germany |
| University Clinic Ulm | Ulm | 89075 | Germany |
| University Clinic Würzburg | Würzburg | 97080 | Germany |
| Ospedale Bambino Gesu Roma | Rome | 00165 | Italy |
| Ospedale Infantile Regina Margherita Torino | Turin | 10126 | Italy |
| Bydgoszcz Medical University | Bydgoszcz | 85-094 | Poland |
| Kraków Medical University | Krakow | 30-663 | Poland |
| Lublin Medical University | Lublin | 20-093 | Poland |
| Wroclaw Medical University | Wroclaw | 50-368 | Poland |
| Birmingham Children's Hospital | Birmingham | B4 6NH | United Kingdom |
| Central Manchester University Hospital | Manchester | M13 9WL | United Kingdom |
| Sheffield Children's Hospital | Sheffield | S10 2TH | United Kingdom |
| ID | Term |
|---|---|
| D009190 | Myelodysplastic Syndromes |
| ID | Term |
|---|---|
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C018404 | treosulfan |
Not provided
Not provided
Not provided